These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 6399222)
41. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465 [TBL] [Abstract][Full Text] [Related]
42. [The value of the immunoglobulin G avidity test for the serologic diagnosis of brucellosis]. Kutlu SS; Celikbaş A; Ergönül O; Kutlu M; Aksaray S; Güvener E; Dokuzoğuz B Mikrobiyol Bul; 2003 Oct; 37(4):261-7. PubMed ID: 14748263 [TBL] [Abstract][Full Text] [Related]
43. Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella cytoplasmic proteins in chronic human brucellosis. Giambartolomei GH; Delpino MV; Cahanovich ME; Wallach JC; Baldi PC; Velikovsky CA; Fossati CA J Infect Dis; 2002 Jul; 186(2):252-9. PubMed ID: 12134263 [TBL] [Abstract][Full Text] [Related]
44. [Practical value of examining cellular immunity in human brucellosis]. Bertrand A; Siffert M; Bascoul S; Mathieu-Daudé JC Dev Biol Stand; 1984; 56():537-46. PubMed ID: 6489630 [No Abstract] [Full Text] [Related]
45. Cellular bioterrorism: how Brucella corrupts macrophage physiology to promote invasion and proliferation. Jimenez de Bagues MP; Dudal S; Dornand J; Gross A Clin Immunol; 2005 Mar; 114(3):227-38. PubMed ID: 15721833 [TBL] [Abstract][Full Text] [Related]
46. [Comparative investigations using the complement fixation test and the agar gel immunodiffusion test to reveal the presence of Brucella-ovis-antibodies (author's transl)]. Pózvári M Dtsch Tierarztl Wochenschr; 1980 May; 87(5):182-6. PubMed ID: 6772421 [No Abstract] [Full Text] [Related]
47. Assessment of diagnostic enzyme-linked immunosorbent assay kit and serological markers in human brucellosis. Cakan G; Bezirci FB; Kacka A; Cesur S; Aksaray S; Tezeren D; Saka D; Ahmed K Jpn J Infect Dis; 2008 Sep; 61(5):366-70. PubMed ID: 18806343 [TBL] [Abstract][Full Text] [Related]
48. [Effects of chlortetracycline on intracellular Brucella]. Roux J; Ramuz M; Serre JC Ann Inst Pasteur (Paris); 1969 Jan; 116(1):49-62. PubMed ID: 4890585 [No Abstract] [Full Text] [Related]
49. The recovery of L forms of Brucella and their relation to Brucella phage. NELSON EL; PICKETT MJ J Infect Dis; 1951; 89(3):226-32. PubMed ID: 14888947 [No Abstract] [Full Text] [Related]
50. [Characteristics of S and R forms of brucella]. Parnas J; Zalichta S; Mardarowicz C; Sidor-Wójtowicz A Zentralbl Veterinarmed B; 1967 Dec; 14(8):723-36. PubMed ID: 5602112 [No Abstract] [Full Text] [Related]
51. L-Forms: their biology and role in disease. Feingold DS Med Times; 1969 Jan; 97(1):106-11. PubMed ID: 5762722 [No Abstract] [Full Text] [Related]
53. [Studies of L forms of Brucella. I. Experiments on the isolation of L forms of Brucella]. Christophorov L; Peschkov J Zentralbl Bakteriol Orig; 1969; 209(4):497-504. PubMed ID: 5198059 [No Abstract] [Full Text] [Related]
54. [Persistence of L-forms of Brucella in patient with chronic form of brucellosis]. Mikhaĭlov LM; Kalinovskiĭ AI; Balakhonov SV; Shestopalov MIu; Andreevskaia NM; Mikhaĭlova VA; Borisov VA; Khodus FI; Gordienko LN; Oshchepkov VG Zh Mikrobiol Epidemiol Immunobiol; 2009; (5):114-5. PubMed ID: 20063803 [No Abstract] [Full Text] [Related]
55. [L-forms of Brucella]. Wang QX Zhonghua Liu Xing Bing Xue Za Zhi; 1984 Oct; 5(5):314-7. PubMed ID: 6399222 [No Abstract] [Full Text] [Related]
56. [Persistence of brucellosis L cultures in the body of an experimental animal and the duration of immunity]. Vershilova PA; Grekova NA; Tolmacheva TA Vestn Akad Med Nauk SSSR; 1985; (3):10-3. PubMed ID: 3922151 [No Abstract] [Full Text] [Related]